Cocrystal Pharma raises $5M from OPKO Health; norovirus Phase 1b data expected Q4 2026

Cocrystal Pharma, Inc.

Sold 5,474,053 shares to OPKO at $0.9134/share, gross proceeds $5.0M, no warrants.
Proceeds to fund preclinical/clinical programs, including norovirus Phase 1b trial with topline data by end of Q4 2026.
Dr. Phillip Frost, Chairman/CEO of OPKO, is co-founder, director, and principal stockholder of Cocrystal.
Private placement under Section 4(a)(2) and Regulation D; shares unregistered.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.